GET DAILY SIGNALSWhy Is Repligen Corporation (RGEN) Stock Down -4.13% Today?
Key Takeaways
- Repligen Corporation (RGEN) fell roughly 4.13% in Tuesday's session, slipping from a prior close of $180.17 to about $172.73.
- The decline came despite a third-quarter earnings beat, as investors focused on a GAAP operating loss, filtration-segment weakness, and gross margin pressure.
- Record revenue of $209.3 million and an adjusted EPS beat of $0.53 versus a $0.46 consensus were overshadowed by an intangible-asset impairment charge.
- The company raised full-year 2026 revenue guidance, but the move was not enough to offset near-term concerns.
- Traders are watching whether the selloff stabilizes and how the newly closed BioLife Solutions acquisition integrates in coming quarters.
- For more detail on this ticker, explore Price Targets, Earnings, and Forecast pages.
- To discover active trading strategies for this and other symbols, visit the Trending AI Robots page.
Opening Summary
Repligen Corporation (RGEN), a global bioprocessing company that develops technologies and consumables used in the manufacture of biologic drugs, saw its shares move sharply lower on Tuesday. The stock traded down approximately 4.13% to about $172.73, compared with a prior-session close of $180.17. The decline followed the company's third-quarter 2026 earnings release, in which a top-and-bottom-line beat was eclipsed by a GAAP operating loss and softer performance in its filtration franchise.
Earnings Beat Overshadowed by a GAAP Loss
Repligen (RGEN) reported record third-quarter revenue of $209.3 million, up 11% as reported and 12.5% on an organic basis, driven by strength across its chromatography, proteins, and process analytics franchises. Adjusted earnings per share of $0.53 came in well ahead of the $0.46 consensus, and adjusted EBITDA of $43.8 million also exceeded expectations.
However, the company's GAAP results told a different story. Repligen (RGEN) posted a loss from operations of $29.5 million for the quarter, largely attributable to an intangible-asset impairment charge, and a GAAP loss per share of $0.68, compared with earnings of $0.26 per share a year earlier. The divergence between adjusted and GAAP figures weighed on sentiment, as investors recalibrated expectations around the company's reported profitability.
Filtration Weakness and Margin Pressure
Beyond the headline numbers, markets focused on softness in the company's filtration segment, which posted a low double-digit decline on headwinds from the Polymem divestiture, foreign currency effects, and customer-specific challenges. Adjusted gross margin edged down roughly 30 basis points year over year to about 53%, reflecting an unfavorable product mix even as operating discipline lifted adjusted operating margin.
The combination of filtration softness and margin pressure suggested to some investors that growth remains uneven across the portfolio, tempering enthusiasm for what was otherwise a strong quarter in chromatography and proteins.
Raised Guidance and the BioLife Acquisition
Management raised full-year 2026 revenue guidance to a range of $844 million to $852 million, implying reported growth of 14.5% to 15.5%, and lifted its adjusted EPS outlook to a midpoint of about $2.07. The company also highlighted the October closing of its BioLife Solutions acquisition, which it expects to strengthen its position in the high-growth cell therapy market.
Despite the constructive guidance and the strategic rationale for the deal, the stock's reaction reflected a "show-me" stance among investors, who appeared more focused on near-term execution and the impact of the impairment charge than on the longer-term growth narrative.
Market Context and Trading Activity
The decline in RGEN shares was earnings-driven rather than reflective of broad market weakness, as the move diverged from the broader bioprocessing and healthcare complex. The stock had been a strong performer over the prior three months, gaining more than 25%, which may have left it vulnerable to profit-taking once the quarterly report failed to deliver a clean, all-around beat. Traders are now watching whether the shares can hold key technical support after surrendering the gains that had built up heading into the report.
What Comes Next for RGEN
Looking ahead, investors will monitor the integration of BioLife Solutions, the durability of chromatography and proteins momentum, and any stabilization in the filtration segment. The company's raised guidance signals confidence in end-market demand, but execution against those targets will be closely scrutinized. Risks include continued filtration softness, gross margin fluctuations tied to product mix, and the potential for further impairment or integration costs. The market's next catalyst will likely be management's commentary on fourth-quarter trends and the early contribution from BioLife.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of the platform's strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI-driven trading bots that cover thousands of tickers, each varying by strategy, timeframe, performance metrics, and the symbols they trade. Explore the Trending AI Robots section to see which automated strategies are currently outperforming and to find ideas aligned with your own trading approach.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
RGEN's Indicator enters downward trend
The Aroon Indicator for RGEN entered a downward trend on September 21, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 211 similar instances where the Aroon Indicator formed such a pattern. In 181 of the 211 cases the stock moved lower. This puts the odds of a downward move at 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for RGEN moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 18 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 57 cases where RGEN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for RGEN turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 38 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on RGEN as a result. In 66 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
RGEN moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for RGEN crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
Following a +2.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where RGEN advanced for three days, in 226 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
RGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. RGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.814) is normal, around the industry mean (4.950). RGEN's P/E Ratio (243.473) is considerably higher than the industry average of (37.710). Projected Growth (PEG Ratio) (1.935) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is Convertible Preferred Stock?
What is the relationship between major currencies in general?
Will Having a 529 Plan for My Child Impact His/Her Eligibility For Financial Aid in the Future?
What Is Marxism and Differentiates from Other Socio-Political Theories?
What is the commodity channel index (CCI)?
General Information
a developer of biologic drugs
Industry PharmaceuticalsOther
Advertisement